ArticleScience progress
Integrative evaluation of shear wave elastography and renal function biomarkers for predicting renal fibrosis in chronic kidney disease patients.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveWe hypothesize that combining point shear wave elastography (PSWE) with clinical risk factors enables accurate renal fibrosis assessment. This retrospective study integrates PSWE with serum creatinine (Scr) and estimated glomerular filtration rate (eGFR) to develop and validate a nomogram for personalized renal fibrosis evaluation in chronic kidney disease (CKD) patients.MethodsA total of 157 patients underwent renal PSWE and kidney biopsy. PSWE measured cortical stiffness in the mid-portion of the right kidney. Feature importance was selected using elastic net regression, XGBoost, and random forest, with PSWE, Scr, and eGFR identified as key variables. Three models were established: Model 1 (PSWE + Scr + eGFR), Model 2 (Scr + eGFR), and Model 3 (PSWE). Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC) values. A nomogram based on PSWE, Scr, and eGFR was developed for precise fibrosis risk assessment. The Hosmer-Lemeshow test and K-fold cross-validation were used to evaluate the nomogram's generalizability.ResultsModel 1 achieved an AUC of 0.928, outperforming Model 2 (AUC = 0.878) and Model 3 (AUC = 0.824). The Hosmer-Lemeshow test yielded a
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.